Cargando…

Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524370/ https://www.ncbi.nlm.nih.gov/pubmed/34663642 http://dx.doi.org/10.1136/jitc-2021-003113corr1

Ejemplares similares

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis
por: Allen, Clint T., et al.
Publicado: (2019)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Recurrent respiratory papillomatosis with lung involvement
por: Molodtsova, Valentina, et al.
Publicado: (2018)

Recurrent respiratory papillomatosis: the role of cidofovir
por: Tran, Mai Ngoc, et al.
Publicado: (2018)

Correction To: Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)

Recurrent Respiratory Papillomatosis (RRP)—Juvenile Onset
por: Dyrstad, Sara W., et al.
Publicado: (2008)

Recurrent respiratory papillomatosis: current and future perspectives
por: Carifi, Marco, et al.
Publicado: (2015)

Current and future management of recurrent respiratory papillomatosis
por: Ivancic, Ryan, et al.
Publicado: (2018)

Recurrent respiratory papillomatosis: A 2020 perspective
por: Benedict, Jacob J., et al.
Publicado: (2021)

Efficacy of cidofovir in recurrent juvenile respiratory papillomatosis
por: Valera, Fabiana, et al.
Publicado: (2015)

Systemic Bevacizumab for Severe Recurrent Respiratory Papillomatosis
por: Tatineni, Swetha, et al.
Publicado: (2022)

Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis
por: Broekema, Ferdinand I., et al.
Publicado: (2008)

Recurrent respiratory papillomatosis: an overview of current thinking and treatment
por: Goon, Peter, et al.
Publicado: (2007)

Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis
por: Wierzbicka, Małgorzata, et al.
Publicado: (2011)

Recurrent respiratory papillomatosis (RRP)–time for a reckoning?
por: Kin Cho Goon, Peter, et al.
Publicado: (2017)

Laryngotracheobronchial papillomatosis: an uncommon cause of recurrent respiratory infection
por: Ribeiro, Bruno Niemeyer de Freitas, et al.
Publicado: (2020)

Risk factors associated with severe recurrent respiratory papillomatosis
por: Khan, Muddaseer, et al.
Publicado: (2019)

HPV and Recurrent Respiratory Papillomatosis: A Brief Review
por: Ouda, Amr Mohamed, et al.
Publicado: (2021)

Surgical treatment and adjuvant therapies of recurrent respiratory papillomatosis
por: Avelino, Melissa Ameloti Gomes, et al.
Publicado: (2015)

Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
por: Ribas, Antoni, et al.
Publicado: (2021)

Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

Recurrent Respiratory Papillomatosis Presenting as Worsening Dyspnea in an HIV-infected Patient
por: Gonçalves, Inês C, et al.
Publicado: (2022)

Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis
por: MOHR, MICHAEL, et al.
Publicado: (2014)

Risk Factors for Aggressive Recurrent Respiratory Papillomatosis in Adults and Juveniles
por: Omland, Turid, et al.
Publicado: (2014)

Quality and readability assessment of websites related to recurrent respiratory papillomatosis
por: San Giorgi, Michel R.M., et al.
Publicado: (2017)

Hemoptysis in recurrent respiratory papillomatosis: also think about aspergillosis
por: Dalpiaz, Giorgia, et al.
Publicado: (2018)

An updated review of the epidemiological factors associated with recurrent respiratory papillomatosis
por: Welschmeyer, Alexandra, et al.
Publicado: (2021)

Estimated incidence of juvenile-onset recurrent respiratory papillomatosis in Korea
por: Oh, Jin-Kyoung, et al.
Publicado: (2021)

Epidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis
por: Moldan, Matthew M., et al.
Publicado: (2013)

Divergent Human Papillomavirus Associated with Recurrent Respiratory Papillomatosis with Lung Involvement
por: Yuan, Hang, et al.
Publicado: (2013)

A Case of the Intrapulmonary Spread of Recurrent Respiratory Papillomatosis With Malignant Transformation
por: Xiao, Yang, et al.
Publicado: (2015)

Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir
por: FUSCONI, M., et al.
Publicado: (2014)

Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis
por: Tjon Pian Gi, Robin E. A., et al.
Publicado: (2016)

Juvenile-onset recurrent respiratory papillomatosis with pulmonary involvement and carcinomatous transformation
por: Mitsumoto, Gabriel Lorente, et al.
Publicado: (2018)

Recurrent respiratory papillomatosis with lower airway involvement in a young woman
por: Mamaeva, Tatiana, et al.
Publicado: (2020)

Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
por: Lee, Maxwell Y., et al.
Publicado: (2021)

Virus-Associated Biomarkers in Oropharyngeal and Nasopharyngeal Cancers and Recurrent Respiratory Papillomatosis
por: Murono, Shigeyuki
Publicado: (2021)

A Case of Recurrent Respiratory Papillomatosis With Lung Involvement and Malignant Transformation
por: Valdivia Padilla, Alejandra, et al.
Publicado: (2022)

Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review
por: Pogoda, Louis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f37mbq6pl5chcb8ti8eq20l9mq